Attenuation of quorum sensing in the pathogen *Acinetobacter baumannii* using non-native *N*-acyl homoserine lactones

Danielle M. Stacy¹, Michael A. Welsh¹, Philip N. Rather²,³, and Helen E. Blackwell¹,*

¹Department of Chemistry, University of Madison–Wisconsin, 1101 University Ave., Madison, WI 53706
²Department of Microbiology and Immunology, Emory University School of Medicine, 3001 Rollins Research Center, Atlanta, GA 30322
³Research Service Veterans Affairs Medical Center, 1670 Clairmont Rd., Decatur, GA 30033

Abstract

Many bacterial pathogens use quorum sensing (QS) to control virulence. As a result, the development of methods to intercept QS has attracted significant interest as a potential anti-infective therapy. *Acinetobacter baumannii* has emerged as a pan-drug resistant pathogen and displays a remarkable ability to persist in hospital settings despite desiccation and antimicrobial treatment. Recent studies have shown that *A. baumannii* QS mutants have limited motility and fail to form mature biofilms – these phenotypes are linked to its ability to persist on biotic and abiotic surfaces and increase its pathogenicity. *A. baumannii* uses *N*-(3-hydroxydodecanoyl)-*L*-homoserine lactone (OH-dDHL) and its putative cognate receptor, AbaR, for QS. We sought to identify non-native ligands capable of blocking or promoting AbaR activity in *A. baumannii* for use as chemical probes to modulate QS phenotypes in this pathogen. We screened a focused library of synthetic, non-native *N*-acyl homoserine lactones (AHLs) to identify such compounds, and several highly potent antagonists and agonists were uncovered, with *IC*₅₀ and *EC*₅₀ values in the low micromolar range, respectively. The strongest AbaR antagonists largely contained aromatic acyl groups, whereas the AbaR agonists closely resembled OH-dDHL. Notably, the 10 most potent AbaR antagonists also strongly inhibited *A. baumannii* motility, and five antagonists reduced biofilm formation in *A. baumannii* by up to 40%. The discovery of these compounds is significant, as they represent, to our knowledge, the first non-native modulators of QS in *A. baumannii* to be reported and could find utility as new tools to study the role and timing of QS phenotypes in *A. baumannii* infections.

INTRODUCTION

Bacteria use small molecule or peptidic signals to assess their local population densities in a process termed quorum sensing (QS) (1–3). The concentration of QS signals in a given environment can be correlated with cell density. Once the bacteria reach a sufficiently large population, they will shift from a unicellular to a largely multicellular existence and modify gene expression levels to initiate a broad range of group behaviors that benefit the growing community (4). These QS phenotypes include biofilm formation, virulence factor production, swarming, sporulation, conjugation, and bioluminescence, and often play a

*To whom correspondence should be addressed. blackwell@chem.wisc.edu.*

ASSOCIATED CONTENT

Supporting Information

This material is available free of charge via the Internet at http://pubs.acs.org.
critical role in mediating pathogenic or symbiotic relationships with a eukaryotic host (5–7). For instance, many pathogens will become virulent only after perceiving that a “quorum” of cells has been reached, thus increasing the probability that the bacterial population can survive the host immune response (6, 8). Copious questions remain about QS signaling mechanisms and their roles in host-bacteria interactions, especially in infections, as several of the most deadly human pathogens use QS to control virulence (e.g., Pseudomonas aeruginosa and Staphylococcus aureus). As such, methods to block bacterial QS would be valuable to study this signaling process at a fundamental level and could provide a route to the development of novel anti-infective strategies (9–11).

QS in Gram-negative bacteria has been studied extensively over the past 25 years, and is typically mediated by diffusible N-acyl -homoserine lactone (AHLs) signals (Figure 1A) (12, 13). The AHLs are generated via LuxI-type synthases, and perceived by intracellular LuxR-type receptors that behave as transcriptional activators. The AHL signals are produced at low basal levels, and a sufficient density of cells is required to generate an adequate concentration of AHL for productive LuxR-type receptor binding. The AHL:LuxR-type receptor complexes then typically dimerize, bind to various QS promoters in the bacterial genome, and activate the transcription of genes linked to QS phenotypes. The LuxI/LuxR circuit constitutes the minimal system necessary for QS in Gram-negative bacteria. Several bacteria regulate QS via the complex interplay of multiple LuxI/LuxR circuits, however, and the pathogen P. aeruginosa is a prominent example of such (14, 15).

Interception of LuxI/LuxR-type QS circuits represents one approach to attenuate QS phenotypes in Gram-negative bacteria, and strategies aimed at blocking AHL:LuxR-type receptor binding with either small molecules or macromolecules have attracted considerable attention (10, 16–18). Our laboratory and others have recently uncovered a series of non-native AHLs and AHL analogs that are capable of strongly antagonizing or agonizing LuxR-type receptors in a range of Gram-negative bacteria (16, 18–31). These compounds represent useful chemical probes for the study of QS phenotypes in both pathogens and symbionts, and can provide methods for the spatial and temporal control of QS in range of environments that are challenging using traditional genetic techniques. One of our major goals is to utilize these molecules to examine the role of QS in host-pathogen interactions (32, 33), and we have recently shown that several non-native-AHLs can strongly block virulence in the plant pathogens Pectobacterium carotovora and Pseudomonas syringae on their native plant hosts (34). We now seek to extend these studies to mammalian systems, and we are focused on identifying potent QS modulators in Gram-negative human and animal pathogens. In the current study, we report our investigations of the activity of non-native AHLs in Acinetobacter baumannii, which has recently emerged as a major nosocomial pathogen and uses QS to control phenotypes linked to virulence.

A. baumannii was classified as a relatively low-grade, opportunistic pathogen up until 30 years ago, and was often ignored in clinical settings. The recent development of multi- and pan-drug resistant strains of A. baumannii in hospitals, however, has brought renewed attention to this pathogen. A. baumannii infections cause serious diseases in immunocompromised human hosts, including ventilator-associated pneumonia, septicemia, and urinary tract and wound infections. Further attention has been drawn to these infections due to their incidence in injured US military personnel returning from the Middle East over the past decade. Indeed, A. baumannii has been coined the “Gram-negative MRSA” due to its prevalence and rapid resistance development. The ability of clinical strains to survive desiccation and nutrient starvation in hospital settings makes A. baumannii yet more problematic, allowing it to persist on surfaces for extended periods of time and contributing to frequent infection outbreaks in ICUs (35, 36). For example, certain A. baumannii strains can survive desiccated environments with a mean survival time of 27 days (37, 38). The
ability of *A. baumannii* to persist has been attributed to its capacity to form sessile biofilms on medically relevant biotic and abiotic surfaces (39), and recently biofilm formation in *A. baumannii* has been linked to its LuxI/LuxR-type QS system (AbaI/AbaR, see below). Surface motility, which can play a role in biofilm formation, is also under the control of QS in *A. baumannii* (40). This connection between virulence-associated phenotypes in *A. baumannii* and QS motivated us to examine the activity of our non-native AHLs as QS modulators in this treacherous pathogen.

The only regulatory QS proteins identified in *A. baumannii* to date are a LuxI-type synthase, AbaI, and a putative LuxR-type receptor, AbaR (41, 42). AbaI produces N-(3’-hydroxydodecanoyl)-L-HL (OH-dDHL, Figure 1B), which serves as *A. baumannii*’s primary QS signal. To date, the native stereocchemistry at the 3’-OH position of OH-dDHL (R or S) is yet to be assigned. The synthase AbaI has been isolated and characterized, and the activity of AbaR has been inferred from its homology to other LuxR-type proteins and abaR being adjacent to abai in the *A. baumannii* genome. Notably, *A. baumannii* (ΔabaI) mutants show both reduced biofilm production and limited surface motility, and these traits can only be restored upon addition of OH-dDHL (40, 41). We hypothesized that, similar to other Gram-negative bacteria with LuxI:LuxR-type QS circuits, non-native AHLs could potentially be utilized to intercept AbaR:OH-OdDHL binding and modulate QS phenotypes in *A. baumannii*.

Herein, we report our investigations into the activity of non-native AHLs as AbaR modulators in *A. baumannii*. These studies motivated us to determine the structure of the native AHL signal for this pathogen. We synthesized and tested both diastereoisomers of OH-dDLH as AbaR activators, and obtained results suggesting that (R)-OH-dDHL is likely the native QS signal in *A. baumannii*, in contrast to the recent report of Garner et al. (43). We utilized (R)-OH-dDHL as our positive control to screen a 77-member library of synthetic, non-native AHLs to identify AbaR agonists and antagonists using an *A. baumannii* AbaR reporter strain. Several highly potent compounds were uncovered, with IC_{50} and EC_{50} values in the low micromolar range. The strongest AbaR antagonists largely contained aromatic acyl groups, whereas the AbaR agonists closely resembled (R)-OH-dDHL. The 10 most potent AbaR antagonists also strongly inhibited *A. baumannii* motility in a swarming-type assay, and five of these compounds reduced biofilm formation in *A. baumannii* by up to 40%. The discovery of these compounds is significant, as they represent the first non-native modulators of QS in *A. baumannii* to be reported, and can serve as new tools to study the role and timing of QS phenotypes in *A. baumannii* infections. Further, these compounds provide a first set of SAR data from which to initiate the development of chemical-based, anti-infective strategies against this lethal pathogen.

**RESULTS AND DISCUSSION**

**Natural ligand stereochemistry**

To perform AbaR agonism and antagonism screens in *A. baumannii*, we required the native OH-dDHL signal for use as a control compound. As the stereochemistry of this signal was undefined, we undertook synthetic studies to determine the active stereoisomer of OH-dDHL. The AHL lactone core is derived biosynthetically from S-adenosyl-L-methionine (see below) (44–47), and numerous reports have established that the HL stereocenters in native AHLs are L (18, 48, 49); the D-enantiomers of these AHLs have markedly reduced activity. We therefore reasoned that OH-dDHL also contained a D-HL, and focused our attention on assigning the 3’-OH stereocenter.

Of the ~25 known native AHLs, only a few contain 3’-OH groups and the effects of stereochemistry at this position on activity have not been carefully scrutinized (50).
However, analogous to the HL stereocenter, the biosynthetic pathway for AHLs also provides some guidance in assigning the 3’-stereocenter in OH-dDHL a priori. In AHL biosynthesis, LuxI-type synthases are known to couple S-adenosyl-l-methionine and acyl-acyl carrier protein (acyl-ACP) substrates to produce AHL products (44–47). Acyl-ACPs, the sources of the acyl chain segment of AHLs, are intermediates in fatty acid biosynthesis. One essential step in this cyclical pathway is the reduction of β-ketoacyl-ACP to β-hydroxyacyl-ACP by the enzyme FabG (51), and FabG is known to produce (R)-3-hydroxyacyl-ACP stereoselectively (52). If AbaI, like all other LuxI-type synthases, preferentially selects fatty acid biosynthesis intermediates as substrates, the 3’-stereocenter of OH-dDHL should be (R). In support of this hypothesis, the known native AHLs with 3’-OH groups isolated from Vibrio harveyi, Aeromonas culicola, Phaeobacter gallaeciensis, and Rhizobium leguminosarum (shown in Figures 2A–D) have all been reported to have (R)-stereochemistry (53–55).

To experimentally test this hypothesis in A. baumannii, we synthesized the (R) and (S) diastereoisomers of OH-dDHL, producing the key 3’-OH stereocenter via a Noyori asymmetric hydrogenation (Scheme 1) (56). The compounds were purified to homogeneity using RP-HPLC, with diastereomeric excesses (d.e.) of >99% (see Supporting Information). We tested each diastereomer for its ability to activate the AbaR receptor over a range of concentrations in an A. baumannii reporter strain (ΔabaI) that lacks a functioning AbaI synthase and reports AbaR activity via β-galactosidase production (see Methods). These assays revealed that (R)-OH-dDHL was ~40-fold more active than (S)-OH-dDHL, with EC<sub>50</sub> values of 0.70 µM and 29 µM, respectively. We note that our data conflict with a recent study of Garner et al. (43), who reported that the two diastereomers were of approximately equal activity in the identical A. baumannii reporter strain (EC<sub>50</sub> values of 0.67 µM and 0.82 µM for (R)-OH-dDHL and (S)-OH-dDHL, respectively). While the EC<sub>50</sub> values for (R)-OH-dDHL are identical between these two studies, the reasons for the disparate EC<sub>50</sub> values for (S)-OH-dDHL are currently unclear. Nevertheless, the biological data for (R)-OH-dDHL is likely the primary AHL signal in A. baumannii. We therefore used (R)-OH-dDHL as our native AHL control throughout the remainder of this study.

**Selection of synthetic AHL library**

We next screened a set of synthetic AHLs for their ability to modulate the activity of AbaR, and thereby QS, in A. baumannii. Our laboratory has previously reported several libraries of native and non-native AHLs (19–22, 24, 28), and from this larger set we selected 77 AHLs for study in A. baumannii. These compounds had varied acyl chain structures and displayed a range of activities as LuxR-type protein agonists and antagonists in other bacteria. To simplify their analysis here, we divided this set of AHLs into five sub-libraries (termed the control and A–D libraries; see Supporting Information for full set of structures).

The control library (1–9) contained the native AHL ligands from other Gram-negative bacteria (e.g., P aeruginosa, V. fischeri, and Agrobacterium tumefaciens) and some of the first synthetic LuxR-type protein antagonists that we and others have identified in these species (20, 30, 57). The A library (A1–A8) contained AHLs with unbranched aliphatic acyl groups of differing lengths (4–16 carbons) and with different oxidation states at the 3’-position. The B library (B1–B14) consisted of AHLs with cycloalkyl or aromatic acyl groups, and one-carbon longer or shorter homologs or D-HL analogs of the control library AHLs. The C library (C1–C25) was made up of phenylacetanoyl HLS (PHLs) with substituents on the phenyl ring of varying electronics and size; we have previously shown that PHLs are capable of strongly agonizing and antagonizing a range of LuxR-type
receptors, and subtle changes in phenyl group substituents can have striking effects on their activities (19, 20, 22). Lastly, the D library (D1–D21) consisted of AHLs with a set of structurally diverse acyl substituents to more dramatically probe the effects of acyl chain composition on AHL activity in AbaR.

Non-native AHLs that antagonize AbaR

To identify antagonists of AbaR activity, we screened the AHL libraries at 100 µM against (R)-OH-dDHL at its EC$_{50}$ value (0.70 µM) in the A. baumannii (ΔabaI) reporter strain (see Methods). Performing the primary screen at this ~100:1 non-native:native ligand ratio revealed numerous strong AbaR antagonists, with 22 compounds exhibiting greater than 70% AbaR inhibition. To better compare the relative antagonistic activities of these AHLs, we conducted dose response analyses in the A. baumannii (ΔabaI) reporter strain to determine their IC$_{50}$ values. The extent of AbaR antagonism by six of the 22 AHLs rapidly diminished at concentrations less than 100 µM; however, we were able to determine accurate IC$_{50}$ values for the other 16 AHLs. The IC$_{50}$ values for these compounds are listed in Table 1.

In general, the strongest AbaR antagonists contained aromatic acyl groups, with IC$_{50}$ values less than 20 µM. The only exceptions were the control AHLs 3-oxo-octanoyl-HL (1) and heptanoyl-HL (4). Notably, 4-iodo PHL (C10) and 4-bromo PHL (8), previously identified as moderate to strong inhibitors of numerous other LuxR-type receptors (e.g., TraR, LasR, LuxR, ExpR1, and ExpR2 (20, 22, 23, 34)), were also potent AbaR antagonists (91% and 71%, respectively), further broadening the spectrum of bacterial species in which these ligands display inhibitory activity. In contrast, 2-iodo-PHL (C12) strongly antagonized AbaR (80%) yet is only a modest antagonist of TraR, LasR, LuxR, and other LuxR-type receptors (20, 22, 23, 34). This selective inhibition suggests that PHL C12 could prove useful in experiments requiring specific targeting of AbaR in mixed microbial milieu.

A closer examination of the primary screening data allows for the generation of several SARs for AbaR antagonism by AHLs, and we provide a synopsis of the major trends for the five AHL libraries here. For simple aliphatic and 3-oxo AHLs, maximal AbaR antagonism was observed for AHLs with acyl chains of eight carbons (A3 and 1, 60% and 73%, respectively). This activity diminished for AHLs that contained acyl chains shorter or longer than eight carbons (e.g., AHLs butanoyl HL (A1; 11%) or dodecanoyl HL (A5; 2%)). Interestingly, the most potent AbaR antagonist of this class, 3-oxo-octanoyl-HL (1; 73%; IC$_{50}$ = 2.91 µM), is also the natural AHL ligand for TraR in A. tumefaciens. We have previously shown that 1 is also a strong inhibitor of the LasR (50%, IC$_{50}$ = 0.11 µM) (20, 22). The non-3-oxo analogue of 1, octanoyl-HL (A3), was less active than 1 (60% vs. 73%), suggesting that the 3-oxo group is important for AbaR inhibition by aliphatic AHLs. However, heptanoyl-HL (4) was also a strong AbaR antagonist (75%; IC$_{50}$ = 13.7 µM), indicating that acyl chain length can have a larger impact on ligand activity than oxidation state for aliphatic AHLs. Heptanoyl-HL (4) was first reported as a strong TraR inhibitor by Zhu et al. (57), and we have demonstrated in a series of recent studies that this AHL is a strong inhibitor of almost all of the LuxR-type receptors evaluated in our laboratory (20–22), similar to PHLs 8 and C10.

Several B library members were strong AbaR inhibitors in the primary screen (B4, 68%; B5, 78%; B9, 74%; B10, 72%; B11, 69%). However, their extent of antagonism rapidly diminished at concentrations less 100 µM, which only permitted us to determine an accurate IC$_{50}$ value for the most active AHL, phenylpropanoyl HL B10 (IC$_{50}$ = 11.0 µM). One interesting stereochemical SAR for AbaR antagonism was determined from library B. We have previously shown that two of the D-AHLs in this library, B4 and B5, are only modest
inhibitors of other LuxR-type receptors (i.e., TraR, LasR, LuxR, and QscR) relative to their L-HL analogs (8 and 9, ~2 to 10-fold less active), presumably due to their inverted HL stereochemistry (16, 20, 22, 29). Against AbaR, however, B4 was as strong an AbaR antagonist as its L-HL analogue (8, 68% v. 71% inhibition, respectively). Moreover, B5 was actually more active than its L-HL analogue in AbaR (9, 78% v. 48% inhibition, respectively). These data suggest that AHL-derived AbaR antagonists do not need to have native HL stereochemistry, and contrasts strikingly with our and other previous findings for AHL-based antagonists (20, 22).

The C library contained some of the strongest AbaR antagonists identified in this study. This result further showcases the PHL as a valuable and general scaffold for the inhibition of LuxR-type receptors (20, 25). Intriguingly, the PHLs displayed a pattern of activity and SARs in AbaR that were largely analogous to those that we have previously observed for PHLs in LasR from P. aeruginosa (20, 22). Among the halogenated PHLs, antagonistic activity increased with the increasing size and decreasing electronegativity of the halogen. For example, fluoro PHLs (C2–C4) were weakly inhibitory, chloro (C5–C7) and bromo (10, C8, and C9) PHLs were moderately to strongly inhibitory, and iodo PHLs (C10–C12) were strongly inhibitory. Also, nitro PHLs (C13–C15) were less active than chloro PHLs (C14: IC50 = 8.0 µM v. C6: IC50 = 5.47 µM), yet more active than fluoro PHLs (e.g., C2: IC50 > 25 µM). In general, placement of a substituent at the 3-position of the PHL aromatic ring led to stronger AbaR inhibition in all cases; antagonistic activity was diminished for substituents in the 2- and 4-positions. Again, this activity trend is congruent with that observed with these PHLs against LasR, suggesting that the mode of inhibition by this class of non-native AHLs in AbaR and LasR could be similar. As these two receptors share an almost identical native ligand (2 [often termed OdDHL] for LasR v. (R)-OH-dDHL for AbaR), only differing in oxidation at the AHL 3’-position, such analogous SARs for inhibition are perhaps not unexpected. We return to this point below.

The more structurally diverse D library contained only a few moderate AbaR antagonists, with D3 (IC50 = 19.9 µM) and D15 (IC50 = 5.75 µM) representing the most active AHLs. Previous studies have shown that D3 is a modest QscR inhibitor and that D15 is a strong TraR and LasR inhibitor (IC50 = 0.46 µM and 4.67 µM, respectively) (20, 23), and our results here serve to broaden the activity of these two ligands against LuxR-type receptors. Otherwise, the D library was largely inactive as AbaR antagonists, suggesting that sterically bulky acyl groups on non-native AHLs serve to limit their inhibitory activity against AbaR.

Non-native AHLs that agonize AbaR

We next examined the ability of the AHL libraries to agonize AbaR using the A. baumannii (ΔabaI) reporter strain. Each compound was tested for AbaR activation at 100 µM (see Methods). Relative to (R)-OH-dDHL at 100 µM in (set to 100%), only six AHLs were capable of any level of AbaR agonism (2, 62%; A8, 9%; C23, 9%; D13, 16%; D18, 31%; and D19, 9%; see Supporting Information for full screening data). Far fewer non-native AHL agonists of LuxR-type receptors have been identified to date relative to non-native antagonists, and thus these data in AbaR are congruent with prior findings by our lab and others (18, 22). This set of AHLs did not have any structural homology, and only AHL 2 and D18 (Figure 3) were active and soluble over a concentration range that enabled determination of their EC50 values, which were five to 10-fold greater than (R)-OH-dDHL (4.89 µM and 7.57 µM, respectively (Table 1)).

Despite their moderate agonistic activities, AHLs 2 and D18 are worthy of some further discussion in comparison to their activity in LasR. As highlighted above, AHL 2 (or OdDHL) is actually the native ligand for LasR, and is nearly identical to (R)-OH-dDHL. In
view of this structural similarity, it is not surprising that 2 is also capable of AbaR activation. However, its lowered activity relative to (R)-OH-dDHL suggests that the oxidation state at the 3’-position is critical to AbaR agonism by such aliphatic AHLs. In addition, the reduced analog of (R)-OH-dDHL, dodecanoyl-HL (A5), displayed no agonistic activity in AbaR, further supporting the requirement for the 3’-OH group. AHLs with 3-oxo acyl chains longer or shorter than 12 carbon atoms (i.e., A8, A7, 3, and 1) displayed limited AbaR agonism, dropping rapidly from 62% (2) to 10% and 3% for tetradecanoyl-HL (A8) and decanoyl-HL (A7), respectively. No other chain lengths were active agonists, indicating that a 12-carbon acyl group, along with a 3-oxo group, is essential for strong AbaR agonism. AHLs with 3-oxo acyl chains longer or shorter than 12 carbon atoms (i.e., A8, A7, 3, and 1) displayed limited AbaR agonism, dropping rapidly from 62% (2) to 10% and 3% for tetradecanoyl-HL (A8) and decanoyl-HL (A7), respectively. No other chain lengths were active agonists, indicating that a 12-carbon acyl group, along with a 3-oxo group, is essential for strong AbaR agonism. With regard to D18 (EC$_{50}$ = 4.89 µM), this bulky AHL has previously been shown to be an agonist of LasR (EC$_{50}$ = 0.47 µM) (20). This shared activity trend could suggest a similar mode of receptor activation by D18 for the two receptors. We note, however, that preliminary analyses of primary sequence alignments between AbaR and LasR (data not shown) indicate that residues in the putative ligand binding site of AbaR are different from those conserved between LasR and other LuxR-type receptors (e.g., W60, D73, and R61 in LasR (14)), suggesting that these ligand activity similarities may not be correlated to binding site similarities. These differences also obscure our understanding of the origins of the shared trends in PHL-based antagonism for AbaR and LasR discussed above (assuming that these ligands act directly via receptor binding). On the other hand, this dissimilarity could help to explain the strong activities of certain D-AHLs in AbaR relative to other LuxR-type receptors (see above). Further analysis of sequence alignments and AHL activity trends between AbaR and LasR (along with other receptors) are required, and are being pursued as part of ongoing mechanistic studies of non-native AHLs in our laboratory.

**Synthetic AbaR antagonists limit *A. baumannii* motility**

We sought to determine whether the AbaR antagonists identified above in reporter gene assays were also able to inhibit a phenotype linked to QS in *A. baumannii*, and we selected motility as our first phenotype for testing. Although *A. baumannii* has previously been classified as non-motile, it is capable of a rapid form of motility on low agar (0.3%) that is straightforward to quantify by measuring bacterial migration distances after fixed time intervals (40). This motility appears to be due to a combination of twitching motions mediated by type-IV pili and sliding motility. Motility is severely reduced in the *A. baumannii* (ΔabaI) mutant (75% reduction relative to wild-type M2), but is restored to wild-type levels when agar plates are supplemented with the native QS signal (R)-OH-dDHL (40). We thus tested the 10 most potent AbaR antagonists uncovered above (AHLs 1, B10, C6, C8, C10–C12, C14, C20, and D15) for their ability to inhibit (R)-OH-dDHL mediated rescue of motility in the *A. baumannii* (ΔabaI) mutant (see Methods for assay details).

We were pleased to observe that three of the AbaR antagonists (1, C8, and C11) were potent inhibitors of *A. baumannii* motility, preventing migration at concentrations less than 20 µM that were comparable to the *A. baumannii* (ΔabaI) mutant (Figures 4A). These compounds represent, to our knowledge, the first motility inhibitors to be reported in this pathogen. The two strongest AbaR antagonists in the β-galactosidase reporter assays, AHLs 1 and C11 (Table 1), were also the two strongest motility inhibitors (see Figures 4A and 4B). In addition, SAR trends for the 10 AHLs tested in the motility assay paralleled the SAR observed in the reporter assays. Among the halogenated PHLs, the 3-chloro PHL (C6, IC$_{50}$ value = ~40 µM) was more active than 3-nitro PHL (C14, ~70 µM), yet less active than the 3-iodo PHL (C11, ~15 µM), and the 3-bromo PHL (C8, ~7 µM) was the most active of this series. Further, placement of the iodo substituent at the 3-position (as in PHL C11) led to the strongest motility inhibition, and its placement at the 2-position (C12, ~40 µM) or 4-position (C10, ~70 µM) led to diminished inhibition, in accord with the reporter assay data. Overall, these results indicate that chemical inhibition of AbaR in *A. baumannii* using non-native
AHLs results in motility inhibition, and are in accord with the genetic model that AbaR regulates this phenotype in *A. baumannii*.

**Synthetic AbaR antagonists inhibit *A. baumannii* biofilm formation**

We next investigated the ability of the AbaR antagonists to inhibit biofilm formation in *A. baumannii*. Previous studies have shown that the *A. baumannii* (ΔabaI) mutant formed ~40% less biofilm than wild-type *A. baumannii* (as observed by crystal violet staining), and that wild-type biofilm formation can be fully restored in the mutant through the exogenous addition of (R)-OH-dDHL (41). We therefore tested our top 10 AbaR antagonists for their ability to inhibit biofilm recovery in *A. baumannii* (ΔabaI) (see Methods). The crystal violet biofilm quantification data is shown in Figure 4C. Five of the AHLs (1, C8, C10, C20, and D15) were observed to inhibit biofilm formation to significant levels. Moreover, the three most active AHLs (C8, C10, and D15) not only reduced biofilm recovery in *A. baumannii* (ΔabaI) by ~40%, but also inhibited biofilm formation in wild-type *A. baumannii* by ~40% (see Figure S-12 in Supporting Information). These results are important, as small molecule inhibitors of bacterial biofilm formation are rare in general (10, 58, 59), and to our knowledge, no LuxR-type receptor inhibitors that also attenuate biofilm formation in *A. baumannii* are known (60, 61). Notably, the most potent *A. baumannii* biofilm inhibitor (3-bromo PHL C8) was also one of the most active AbaR antagonists identified in the *A. baumannii* reporter strain and motility assays. The reasons for the somewhat lower activities of AHLs 1 and C11 in the biofilm assay, both potent inhibitors in the reporter and motility assays, relative to C8 are currently unclear. Nonetheless, these biofilm assay data for AHLs 1, C8, C10, C20, and D15 provide further support for the application of small molecule AbaR antagonists for the attenuation of QS-regulated phenotypes in *A. baumannii*.

**Summary and outlook**

*A. baumannii* is an emerging human pathogen and utilizes QS to control at least a subset of phenotypes linked to virulence, including surface motility and biofilm formation. Methods to modulate QS in this bacterium with spatial and temporal control could provide valuable new insight into the role of QS in the infection process, and to date are currently lacking in the field. Herein, we have outlined the first study aimed at the identification of non-native small molecules capable of intercepting a putative QS receptor in *A. baumannii*, AbaR.

There were several important outcomes of our work. First, the synthesis and testing of both (S)-OH-dDHL and (R)-OH-dDHL as AbaR activators revealed the latter molecule to be the most active diastereomer. We propose that, in view of the known AHL biosynthetic pathways and the other structurally characterized 3'-OH AHL signals, (R)-OH-dDHL is likely the native signal in *A. baumannii*. Second, using an *A. baumannii* AbaR reporter strain, we systematically screened a library of synthetic AHLs and uncovered the first known non-native AHLs capable of modulating AbaR activity. Both AbaR antagonists and agonists were identified, and several antagonists were highly potent (for example, AHLs C11 and 1, with IC$_{50}$ values of 2.32 µM and 2.91 µM, respectively). Two AHLs (2 and D18) were identified as moderate AbaR agonists, with EC$_{50}$ values that were only five to 10-fold greater than that of the native signal (R)-OH-dDHL (7.57 µM and 4.89 µM, respectively). Third, careful structural analysis of these molecules revealed important SAR for AbaR antagonism and agonism by non-native AHLs. Perhaps most strikingly, selected D-AHLs were found to be strong antagonists of AbaR and in some cases were equal or stronger antagonists than their L-AHL analogues. This result was unexpected, as D-AHLs are typically far less active than their L-HL analogues in other LuxR-type receptors (e.g., TraR, LasR, LuxR, and QscR) as either antagonists or agonists, and suggests that AbaR may interact with these ligands in a different manner (16, 20, 22, 29). Maximal antagonism was observed for AHLs with aliphatic acyl chains containing seven to eight carbons and a 3'-oxo...
group. AHLs with aromatic acyl groups, most notably the meta-halogenated PHLs, were some of the most potent inhibitors of AbaR, further securing the PHL as a “privileged” scaffold for LuxR-type receptor modulation. Guided by these SARs for AbaR antagonism, synthesis and screening of a focused library of N-(3-hydroxy-4-phenylbutanoyl)-1-LHLs and related OH-AHLs is now underway, and we anticipate that these new compounds may show enhanced AbaR antagonism relative to the AHLs identified in this study through the additive effects of both halogenated aromatic and 3’-OH groups.

Lastly, a fourth and perhaps the most important outcome of this study was the identification of small molecules capable of modulating two important phenotypes in A. baumannii directly linked to QS and virulence. Several of the most potent AbaR antagonists revealed by the reporter gene assays were also found to inhibit A. baumannii surface motility and biofilm production (e.g., AHLs 1, C8, and C11). These compounds represent new and valuable chemical tools to study the role of QS in A. baumannii virulence in both fundamental and applied contexts. As we identified these lead compounds from screening a relatively small set of compounds (77 AHLs), we are optimistic that next-generation abiotic ligands with enhanced activities in AbaR can be generated. Ongoing investigations in our laboratory are focused on such experiments, along with biochemical experiments to elucidate their mechanisms of action, and will be reported in due course.

METHODS

Natural ligand synthesis

(R)- and (S)-OH-dDHL were prepared on a 200 mg scale using reported synthetic methods (56, 62, 63). See Supporting Information for full synthetic details and compound characterization data, including e.e. analysis of intermediates by chiral GC.

Biological reagents and strain information

All biological reagents were purchased from Fisher Scientific and used according to enclosed instructions. Luria–Bertani (LB) medium was prepared as instructed with pH = 7.0. Buffers and solutions (Z buffer, 0.1% (m/v) aqueous SDS, and phosphate buffer) for Miller absorbance assays in A. baumannii were prepared as described (64). The A. baumannii M2 abaI::lacZ (ΔabaI reporter) or A. baumannii M2 (wild-type) strains were used for all bacteriological assays in this study (41). Bacterial cultures were grown in a standard laboratory incubator at 37 °C with shaking (200 rpm) unless noted otherwise. Absorbance measurements were obtained using a Biotek Synergy 2 microplate reader using Gen5 data analysis software. Bacteriological reporter and biofilm assays were performed in triplicate. Motility assays were performed in duplicate.

Compound handling

Stock solutions of synthetic compounds (10 mM) were prepared in DMSO and stored at 4 °C in sealed vials. The amount of DMSO used in small molecule screens did not exceed 2% (v/v). Solvent resistant polypropylene or polystyrene 96-well multititer plates were used when appropriate for small molecule screening. The concentrations of synthetic AHL ligand used in the primary antagonism and agonism assays and the relative ratios of synthetic ligand to (R)-OH-dDHL (100 µM: 0.70 µM) in the antagonism assays were chosen to provide the greatest dynamic range between inhibitors and activators for each bacterial reporter strain. The concentration of (R)-OH-dDHL used in the antagonism assays was equal to its EC_{50} value in the A. baumannii (ΔabaI) reporter strain.
Reported gene assay (β-galactosidase) protocol

For primary agonism assays, 2 µL of concentrated control or AHL stock solution (to give a final concentration of 100 µM) was added to wells in a 96-well multititer plate. An overnight culture of the A. baumannii (ΔabaI) reporter strain (OD$_{600}$ = 1.2) was diluted 1:100 with fresh LB. A 198 µL portion of the diluted culture was added to each well of the multititer plate containing AHLS. Plates were incubated statically at 37 °C for 18–24 h. The cultures were then assayed for β-galactosidase activity following the standard Miller assay method, with the exception that the enzyme was incubated with the substrate o-nitrophenyl-β-D-galactopyranoside (ONPG) at 55 °C (64). Briefly, the OD$_{600}$ of each well of the 96-well multititer plate was recorded. Next, 50 µL aliquots from each well were transferred to a solvent resistant 96-well multititer plate containing 200 µL Z buffer, 8 µL CHCl$_3$, and 4 µL 0.1%(w/v) aqueous SDS. This suspension was mixed via repetitive pipetting (30x), after which the CHCl$_3$ was allowed to settle. A 150-µL aliquot from each well was transferred to a fresh 96-well multititer plate, 20 µL of ONPG (4 µg mL$^{-1}$ in phosphate buffer) was added to each well at time zero, and the plate was incubated at 55 °C for 20 min. Thereafter, the enzymatic reaction was terminated by the addition of 50 µL of 1 M Na$_2$CO$_3$. Absorbance at 420 and 550 nm were measured for each well using a plate reader, and Miller units were calculated according to standard methods (64). Primary AbaR antagonism assays were performed in a similar manner except that the AHL was screened at 100 µM against 0.70 µM (R)-OH-dDHL.

Dose response reporter gene assays

The dose response reporter gene assays were performed according to the protocols outlined above, except that the concentrations of AHLS were varied between $1 \times 10^{-3}$ and $1 \times 10^5$ nM. IC$_{50}$ and EC$_{50}$ values were calculated using GraphPad Prism software (v. 4.0) using a sigmoidal curve fit.

A. baumannii motility assay protocol

Motility assays were performed in 6-well microtiter plates (35 mm wide well) using 0.3% (w/v) Eiken soft agar prepared either unsupplemented or supplemented with 250 µM of (R)-OH-dDHL (added when the agar temperature was approximately 50–55 °C). AHL antagonists were added to wells in two-fold decreasing concentrations, 3 mL of agar was added to each well, and the agar was allowed to set. A 3 mL LB culture of the A. baumannii (ΔabaI) reporter strain was inoculated from a glycerol freezer stock and incubated overnight (to an OD$_{600}$ = 1.2). A 1 µL spot of A. baumannii (ΔabaI) was added to the center of each agar well, and the plate was incubated at 30 °C without shaking. The plate was monitored until bacterial surface migration in the control well (250 µM (R)-OH-dDHL) reached the edge of the agar (35 mm). The migration in all other wells was then measured.

A. baumannii biofilm assay protocol

A 10-mL culture of A. baumannii (wild-type or ΔabaI mutant) was incubated overnight (to an OD$_{600}$ ~ 1.35). A 1:100 dilution of this culture was prepared by centrifugation of a 100 µL aliquot of the overnight culture (3,000 rpm, 1,000 g, 10 min), removal of the supernatant, and re-suspension of the cell pellet in 9.95 mL of 50% LB medium (1:1, LB:18 MΩ H$_2$O). A 50-µL aliquot of concentrated AHL stock solution was then added to give a final compound concentration of 100 µM (0.5% DMSO final). Next, 3-mL aliquots of the diluted culture with AHL were added to test tubes (16x100 mm, borosilicate glass), and the cultures were grown statically at 30 °C for 24 h to allow for robust biofilm growth at the air-water interface. After incubation, a 200-µL aliquot was taken from the center of each tube and the OD$_{600}$ measured. The remaining culture was carefully poured off and the attached biofilm washed with H$_2$O (3.5 mL, 2x) to remove non-adherent cells. Biofilms were then stained.
with a crystal violet (CV) solution (0.1% CV w/v in 95:5 H₂O:EtOH) for 15 min. The stain was poured off and the biofilms were washed with H₂O (3.5 mL, 2x). The tubes were then dried at 37 °C for at least 8 h.

The amount of biofilm formed at the air-liquid interface in each tube was quantified by resolubilizing the CV in acetic acid (30% aq) as follows: AcOH (2.5 mL) was added to the tube, gently mixed by micropipette to wash the bottom of the tube yet avoid contact with the biofilm (to remove any residual background staining of the bottom of the tube not associated with interfacial biofilm), and this washing was removed. Then, fresh AcOH (300 µL) was added to each tube, and the biofilm ring formed at the air-water interface was dissolved by carefully rinsing the tube using micropipette. A 200-µL aliquot of the resulting solution was removed, and the amount of CV was quantified by reading absorbance at 590 nm and normalizing to cell density per tube.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

The NIH (AI063326), ONR (N00014-07-1-0255), Greater Milwaukee Foundation Shaw Scientist Program, Burroughs Wellcome Fund, and Johnson & Johnson provided generous financial support for this work. D.M.S. was funded in part by an NSF Graduate Fellowship (DGE-0718123). We gratefully acknowledge Dr. Robert McClain for assistance with GC experiments and T. M. J. Beary for editorial comments.

**REFERENCES**


Figure 1.
Structures of N-acyl ω-homoserine lactones (AHLs). A. Generic native AHL structures. B. The structure of N-(3'-hydroxydodecanoyl)-ω-HL (OH-dDHL), the predominate autoinducer produced by *A. baumannii*. Stereochemistry at the 3'-position is shown as undefined.
Figure 2.
Figure 3.
Selected agonists and antagonists of AbaR identified in the *A. baumannii* (ΔabaI) reporter strain, and other AHLs of interest noted in the text. Compound numbers match the original numbering schemes from our previously reported control AHLs and AHL libraries A–D (20).
Figure 4.
A. *A. baumannii* (ΔabaI) mobility inhibition assay data for selected AbaR antagonists. Migration distance reports colony mobility over 6–7 h on 0.3% (w/v) Eiken soft agar at 30 °C. Positive control (POS) = (R)-OH-dDHL supplemented agar; Negative control (NEG) = agar alone. See Methods. B. Image of motility assay. Top left, *A. baumannii* (ΔabaI). Top right, *A. baumannii* (ΔabaI) on (R)-OH-dDHL supplemented agar. Bottom left, *A. baumannii* (ΔabaI) on (R)-OH-dDHL and 1 (5 µM) supplemented agar. Bottom right, *A. baumannii* (ΔabaI) on (R)-OH-dDHL and C8 (10 µM) supplemented agar. C. *A. baumannii* (ΔabaI) biofilm inhibition assay data for selected AbaR antagonists at 100 µM. Percent biofilm growth reports crystal violet quantification (Abs$_{590}$) after 24 h growth at 37 °C. Negative control (NEG) = DMSO alone; positive control (POS) = 250 nM (R)-OH-dDHL in DMSO. See Methods.
Scheme 1.
Synthetic route to (R)-OH-dDHL. The same route was used to synthesize (S)-OH-dDHL, except that (S)-(−)-BINAP was used in step c. Reagents and conditions: (a) bis(TMS) malonate, n-BuLi, Et₂O, −60 °C, 1 h, then warm to −10 °C, 5 h. (b) (CH₃)₃SiCHN₂ (2M in Et₂O), benzene:CH₃OH (4:1), 0 °C, 10 min, then warm to 25 °C, 1 h. (c) (i) [(R)-(+) -BINAP]RuBr₂(CH₃OH)₂, H₂ (g), MeOH, 50 °C, 5 h; (ii) NaOH, MeOH, 25 °C, 14 h. (d) L-homoserine lactone·HBr, TEA, EDC·HCl, CH₃CN:H₂O (1:2), 25 °C, 14 h. Abbreviations: BINAP = (1,1′-Binaphthalene-2,2′-diyl)bis(diphenylphosphine), TEA = triethylamine, EDC = 1-Ethyl-3-(3-dimethyl aminopropyl)carbodiimide.
Table 1

Primary antagonism and agonism assay data and IC\textsubscript{50} and EC\textsubscript{50} values for the most active AbaR modulators identified in \textit{A. baumannii} (ΔabaI).\[a\]

<table>
<thead>
<tr>
<th>Compound</th>
<th>Inhibition [%][b]</th>
<th>IC\textsubscript{50} (µM)[c]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>73</td>
<td>2.91</td>
</tr>
<tr>
<td>4</td>
<td>75</td>
<td>13.7</td>
</tr>
<tr>
<td>8</td>
<td>71</td>
<td>7.83</td>
</tr>
<tr>
<td>B10</td>
<td>72</td>
<td>11.0</td>
</tr>
<tr>
<td>C5</td>
<td>78</td>
<td>16.7</td>
</tr>
<tr>
<td>C6</td>
<td>83</td>
<td>5.47</td>
</tr>
<tr>
<td>C7</td>
<td>83</td>
<td>18.5</td>
</tr>
<tr>
<td>C8</td>
<td>90</td>
<td>5.06</td>
</tr>
<tr>
<td>C9</td>
<td>97</td>
<td>17.5</td>
</tr>
<tr>
<td>C10</td>
<td>91</td>
<td>7.06</td>
</tr>
<tr>
<td>C11</td>
<td>91</td>
<td>2.32</td>
</tr>
<tr>
<td>C12</td>
<td>80</td>
<td>6.13</td>
</tr>
<tr>
<td>C14</td>
<td>70</td>
<td>8.00</td>
</tr>
<tr>
<td>C20</td>
<td>91</td>
<td>9.37</td>
</tr>
<tr>
<td>D3</td>
<td>72</td>
<td>19.9</td>
</tr>
<tr>
<td>D15</td>
<td>72</td>
<td>5.75</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Activation [%][d]</th>
<th>EC\textsubscript{50} (µM)[e]</th>
</tr>
</thead>
<tbody>
<tr>
<td>(R)-OH-dDHL</td>
<td>100</td>
</tr>
<tr>
<td>(S)-OH-dDHL</td>
<td>90</td>
</tr>
<tr>
<td>2</td>
<td>62</td>
</tr>
<tr>
<td>D18</td>
<td>31</td>
</tr>
</tbody>
</table>

[a] See Methods for details of reporter strain. See Supporting Information for plots of dose response curves. All assays performed in triplicate.

[b] AHLs evaluated at 100 µM against (R)-OH-dDHL at 0.70 µM. Error ±10%.

[c] IC\textsubscript{50} values determined by testing AHLs over a range of concentrations (10 nM – 100 µM) against (R)-OH-dDHL at 0.70 µM.

[d] AHLs evaluated at 100 µM and normalized to (R)-OH-dDHL at 100 µM (set to 100%). Error ±10%

[e] EC\textsubscript{50} values determined by testing AHLs over a range of concentrations (200 pM – 200 µM).